Comprehensive Stock Comparison
Compare Inhibrx Biosciences, Inc. (INBX) vs ImmunityBio, Inc. (IBRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | IBRX | 22.7% revenue growth vs INBX's -88.9% |
| Quality / Margins | IBRX | -422.3% net margin vs INBX's -110.8% |
| Stability / Safety | INBX | Beta 0.74 vs IBRX's 1.39 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | INBX | +459.5% vs IBRX's +197.3% |
| Efficiency (ROA) | INBX | -87.4% ROA vs IBRX's -93.2% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapeutics for life-threatening conditions like cancer. It generates no revenue currently — funding operations through equity offerings and partnerships while advancing multiple candidates through clinical trials. Its competitive advantage lies in proprietary single-domain antibody (sdAb) technology platforms that enable creation of multi-specific biologics with potentially superior therapeutic profiles.
ImmunityBio is a clinical-stage biotechnology company developing immunotherapies and vaccines for cancers and infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — though as a pre-commercial biotech, it currently relies heavily on equity financing and grants to fund its clinical trials. The company's competitive advantage lies in its integrated immunotherapy platform that combines multiple immune system activation approaches — including antibody cytokine fusion proteins, natural killer cells, and T-cell therapies — which could potentially create synergistic treatment effects.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
IBRX leads in 2 of 6 categories (Financial Metrics, Valuation Metrics). INBX leads in 1 (Profitability & Efficiency). 2 tied.
Financial Metrics (TTM)
IBRX is the larger business by revenue, generating $83M annually — 59.0x INBX's $1M. IBRX is the more profitable business, keeping -4.2% of every revenue dollar as net income compared to INBX's -110.8%.
| Metric | INBXInhibrx Bioscienc… | IBRXImmunityBio, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $83M |
| EBITDAEarnings before interest/tax | -$151M | -$245M |
| Net IncomeAfter-tax profit | -$155M | -$349M |
| Free Cash FlowCash after capex | -$143M | -$324M |
| Gross MarginGross profit ÷ Revenue | -86.3% | +94.8% |
| Operating MarginEBIT ÷ Revenue | -110.0% | -3.2% |
| Net MarginNet income ÷ Revenue | -110.8% | -4.2% |
| FCF MarginFCF ÷ Revenue | -102.5% | -3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +4.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +40.8% |
Valuation Metrics
| Metric | INBXInhibrx Bioscienc… | IBRXImmunityBio, Inc. |
|---|---|---|
| Market CapShares × price | $1.1B | $9.6B |
| Enterprise ValueMkt cap + debt − cash | $930M | $10.0B |
| Trailing P/EPrice ÷ TTM EPS | 0.64x | -15.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5373.68x | 653.30x |
| Price / BookPrice ÷ Book value/share | 8.03x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
| Metric | INBXInhibrx Bioscienc… | IBRXImmunityBio, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -4.2% | — |
| ROA (TTM)Return on assets | -87.4% | -93.2% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -169.3% | -88.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.06x | — |
| Net DebtTotal debt minus cash | -$145M | $361M |
| Cash & Equiv.Liquid assets | $153M | $143M |
| Total DebtShort + long-term debt | $8M | $504M |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | -2.48x |
Total Returns (with DRIP)
A $10,000 investment in INBX five years ago would be worth $25,954 today (with dividends reinvested), compared to $2,937 for IBRX. Over the past 12 months, INBX leads with a +459.5% total return vs IBRX's +197.3%. The 3-year compound annual growth rate (CAGR) favors IBRX at 58.8% vs INBX's 46.1% — a key indicator of consistent wealth creation.
| Metric | INBXInhibrx Bioscienc… | IBRXImmunityBio, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -1.2% | +384.2% |
| 1-Year ReturnPast 12 months | +459.5% | +197.3% |
| 3-Year ReturnCumulative with dividends | +211.6% | +300.8% |
| 5-Year ReturnCumulative with dividends | +159.5% | -70.6% |
| 10-Year ReturnCumulative with dividends | +263.5% | +42.2% |
| CAGR (3Y)Annualised 3-year return | +46.1% | +58.8% |
Risk & Volatility
INBX is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than IBRX's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | INBXInhibrx Bioscienc… | IBRXImmunityBio, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 1.39x |
| 52-Week HighHighest price in past year | $94.56 | $12.43 |
| 52-Week LowLowest price in past year | $10.81 | $1.83 |
| % of 52W HighCurrent price vs 52-week peak | +78.4% | +78.7% |
| RSI (14)Momentum oscillator 0–100 | 47.2 | 65.0 |
| Avg Volume (50D)Average daily shares traded | 165K | 32.7M |
Analyst Outlook
Wall Street rates INBX as "Buy" and IBRX as "Buy".
| Metric | INBXInhibrx Bioscienc… | IBRXImmunityBio, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $11.00 |
| # AnalystsCovering analysts | 5 | 5 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | 100 | 398.59 | +298.6% |
| ImmunityBio, Inc. (IBRX) | 100 | 91.9 | -8.1% |
Inhibrx Biosciences… (INBX) returned +160% over 5 years vs ImmunityBio, Inc. (IBRX)'s -71%. A $10,000 investment in INBX 5 years ago would be worth $25,954 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | $7M | $200000.00 | -97.0% |
| ImmunityBio, Inc. (IBRX) | $236000.00 | $15M | +6147.9% |
ImmunityBio, Inc.'s revenue grew from $0M (2015) to $15M (2024) — a 58.3% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -124.0% | 8437.9% | +6903.1% |
| ImmunityBio, Inc. (IBRX) | -1003.7% | -28.0% | +97.2% |
ImmunityBio, Inc.'s net margin went from -1004% (2015) to -28% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -0.23 | 116.58 | +50787.0% |
| ImmunityBio, Inc. (IBRX) | -0.73 | -0.62 | +15.1% |
ImmunityBio, Inc.'s EPS grew from $-0.73 (2015) to $-0.62 (2024).
Chart 5Free Cash Flow — 5 Years
Inhibrx Biosciences, Inc. generated $-197M FCF in 2024 (-143% vs 2021). ImmunityBio, Inc. generated $-398M FCF in 2024 (-29% vs 2021).
INBX vs IBRX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is INBX or IBRX a better buy right now?
Inhibrx Biosciences, Inc. (INBX) offers the better valuation at 0.6x trailing P/E, making it the more compelling value choice. Analysts rate Inhibrx Biosciences, Inc. (INBX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INBX or IBRX?
Over the past 5 years, Inhibrx Biosciences, Inc. (INBX) delivered a total return of +159.5%, compared to -70.6% for ImmunityBio, Inc. (IBRX). A $10,000 investment in INBX five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: INBX returned +263.5% versus IBRX's +42.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INBX or IBRX?
By beta (market sensitivity over 5 years), Inhibrx Biosciences, Inc. (INBX) is the lower-risk stock at 0.74β versus ImmunityBio, Inc.'s 1.39β — meaning IBRX is approximately 89% more volatile than INBX relative to the S&P 500.
04Which has better profit margins — INBX or IBRX?
Inhibrx Biosciences, Inc. (INBX) is the more profitable company, earning 8438% net margin versus -28.0% for ImmunityBio, Inc. — meaning it keeps 8438% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IBRX leads at -23.3% versus -1657.2% for INBX. At the gross margin level — before operating expenses — IBRX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — INBX or IBRX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is INBX or IBRX better for a retirement portfolio?
For long-horizon retirement investors, Inhibrx Biosciences, Inc. (INBX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.74), +263.5% 10Y return). Both have compounded well over 10 years (INBX: +263.5%, IBRX: +42.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between INBX and IBRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INBX is a small-cap deep-value stock; IBRX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.